Legend's LB2501 in vivo CAR-T shows 83.3% complete-response rate in early clinical data

Legend Biotech / Johnson & Johnson

Early clinical data from LB2501, Legend's next-generation in vivo CAR-T therapy, showed an 83.3% complete-response rate at one dose level. The company plans to file an IND (Investigational New Drug) application with the FDA by year-end 2026 to begin human studies.

• LB2501 early data shows 83.3% complete-response rate at one dose level
• In vivo CAR-T approach generates CAR-T cells within the patient, potentially simplifying manufacturing
• U.S. IND filing planned by year-end 2026
• Next-generation approach targets further commercialization beyond CARVYKTI